11:03 AM EDT, 07/09/2024 (MT Newswires) -- Humacyte ( HUMA ) signed an agreement to license Pluristyx's PluriBank induced Pluripotent Stem Cell line as starting materials to manufacture insulin-producing cells for its BioVascular Pancreas product candidate, Pluristyx said Tuesday.

BioVascular Pancreas is under development as a potential treatment for type 1 diabetes.

Financial terms of the agreement weren't disclosed.

Pluristyx said the deal also gives Humacyte ( HUMA ) access to its panCELLa platform, which enables the generation of "hypoimmune" cells for clinical implantation.

Price: 5.66, Change: -0.01, Percent Change: -0.26